Merck Confirms Guidance for 2022 and Delivers Strong Organic Growth in Q3

14 November 2022 | Monday | News

Merck continued to grow in the third quarter of 2022 despite a challenging external operating environment. Group sales increased by 16.8% to € 5,806 million.
Image Source : Public Domain

Image Source : Public Domain

Results of the third quarter of 2022

  • Group net sales rise by 16.8% to € 5.8 billion
  • Strong organic sales growth of 7.1%, driven by the “Big 3” growth businesses
  • EBITDA pre up by 16.7% to € 1.8 billion thanks to positive earnings developments in Life Science and Healthcare
  • EBITDA pre margin at 31.2%
  • EPS pre comes in at € 2.68
  • Persistent increases in the costs of raw materials, energy and logistics weigh on earnings, especially in Electronics

Forecast for fiscal 2022

  • Forecast for absolute figures at Group level confirmed and further specified
  • Forecast for organic growth of EBITDA pre raised for Life Science, lowered for Electronics

Merck, a leading science and technology company, continued to grow in the third quarter of 2022 despite a challenging external operating environment. Group sales increased by 16.8% to € 5,806 million. The “Big 3” – Process Solutions and Life Science Services, new Healthcare products as well as Semiconductor Solutions – were the key drivers of the strong, 7.1% organic increase in sales. Despite higher costs for raw materials, energy and logistics, EBITDA pre rose organically by 7.5% to € 1,810 million. Higher earnings in the Life Science and Healthcare business sectors contributed to this increase in EBITDA pre.

For fiscal 2022, Merck confirms the mid-point of the absolute ranges for sales, EBITDA pre and EPS pre for the Group level. The company has raised its expectation for organic growth of EBITDA pre of the Life Science business sector yet is lowering it for the Electronics business sector.

“Despite the ongoing turbulence in our external operating environment, we’ve demonstrated our resilience and delivered strong organic growth in sales and EBITDA pre in the third quarter of 2022,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “All three of our business sectors are well-positioned. In Life Science, the core business delivered double-digit growth, more than offsetting the expected decline in pandemic-related sales. The new products and the established portfolio in Healthcare performed strongly. And in Electronics, the renewed double-digit growth of Semiconductor Solutions justifies our confidence in this business.”

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in